A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2014
Price : $35 *
At a glance
- Drugs IPH 5401 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 14 Oct 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials. gov.
- 03 Jun 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials. gov record.
- 25 Feb 2014 Planned End Date changed from 1 Jan 2015 to 1 Oct 2014 as per ClinicalTrials. gov record.